BACKGROUND Vascular access morbidity results in suboptimal patient outcomes and costs more than $8000 per patient-year at risk, representing approximately 15% of total Medicare expenditures for ESRD patients annually. In recent years, the rate of access thrombosis has improved following the advent of vascular access blood flow monitoring (VABFM) programs to identify and treat stenosis prior to ...

Redox reactions of Sb(V) and Sb(III) with mackinawite (FeS) and of aqueous Pu(III) and Pu(V) with various Fe(II)‐bearing minerals and Fe(III)‐oxides have been investigated under anoxic conditions. X‐ ray absorption spectroscopy was used to analyze oxidation state and local coordination environment of Sb and Pu associated with the solid phase. After reaction with mackinawite, chukanovite and...

INTRODUCTION There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017. RESULTS There are 105 agents in the AD treatment development pipeline, of which 25 agents...

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerativ...

lanthanide(iii) chloro complexes of 4[n-(4’-hydroxy-3’-methoxybenzalidene) amino] antipyrine semicarbazone (hmbaaps) (i) and 4[n-(3’,4’,5’-trimethoxybenzalidene) amino] antipyrine semicarbazone (tmbaaps) (ii) with the general composition lncl3.2l (ln = la, pr, nd, sm, gd, tb, dy or ho; l = hmbaaps or tmbaaps) are reported. all the complexes were synthesized in ethanolic medium and refluxed the ...